Skip to main content

Atopic Dermatitis (Eczema) clinical trials at UCLA

5 in progress, 4 open to eligible people

Showing trials for
  • APG777 in Atopic Dermatitis

    open to eligible people ages 18 years and up

    This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

    Los Angeles 5368361, California 5332921 and other locations

  • Barzolvolimab in Patients With Atopic Dermatitis

    open to eligible people ages 18 years and up

    The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

    Los Angeles 5368361, California 5332921 and other locations

  • JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

    Los Angeles 5368361, California 5332921 and other locations

  • Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18 years and up

    The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

    Los Angeles 5368361, California 5332921 and other locations

  • Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

    Los Angeles 5368361, California 5332921 and other locations

Last updated: